Sriram Ryali
Sriram Ryali's purchase track record
Sriram Ryali has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/29/2025 | CRBU | $25K | -36.5% | +53.0% | +5.4% |
| 9/8/2023 | CDXS | $20K | +32.6% | +101.7% | +14.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Codexis Signs siRNA Manufacturing Deal. Codexis has entered an agreement with an unnamed siRNA drug innovator to use its ECO Synthesis platform for stereo-defined fragment synthesis. This partnership highlights the company's manufacturing capabilities in a growing therapeutic area. The stock is currently trading near its 52-week low, with recent price action showing rejection at support levels.
Transaction History
| CRBU | ▲ Buy | Grant | 55,000 | $0 | 2/20/2026 | View on chart |
| CRBU | ▲ Buy | Open Market | 17,360 | $25K | 1/29/2025 | View on chart |
| CDXS | ▲ Buy | Grant | 52,350 | $0 | 1/1/2024 | View on chart |
| CDXS | ▲ Buy | Open Market | 11,650 | $20K | 9/8/2023 | View on chart |
| CDXS | ▲ Buy | Grant | 111,791 | $0 | 2/10/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
No recent news for Caribou Biosciences (CRBU)
There are no recent news releases specifically about Caribou Biosciences in the past week. The stock remains unchanged in terms of public announcements. Technical indicators show RSI at 35.1 and support around $1.59, but without new information the market context is limited.
No recent news for Caribou Biosciences (CRBU). There are no recent news releases specifically about Caribou Biosciences in the past week. The stock remains unchanged in terms of public announcements. Technical indicators show RSI at 35.1 and support around $1.59, but without new information the market context is limited.